Investors Sell 10.4% Stake in Symbiotec Pharmalab Ahead of Rs 1,757 Crore IPO
Ahead of its Rs 1,757-crore IPO opening on August 24, Symbiotec Pharmalab saw a secondary share sale of 10.4 percent stake worth approximately Rs 648 crore. Major shareholders Rosewood Investments and Motilal Oswal's India Business Excellence Fund-III sold a combined 65.57 lakh shares at the upper price band of Rs 988 per share to investors including Think India Opportunities Master Fund, Dymon Asia, ValueQuest, and WhiteOak Capital. The IPO includes a fresh issue of Rs 150 crore and an offer-for-sale of Rs 1,607 crore by promoters and investors.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 42/100.
Outlets measured: freepressjournal, news18, economictimes, mint, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 19 Aug, 03:25 am. Other outlets followed.